Remove

o a collection of information unless it contains a valid OMB control number.

#### Application Number 10712131 Filing Date 2003-11-13 INFORMATION DISCLOSURE First Named Inventor Schabert STATEMENT BY APPLICANT Art Unit 3727 ( Not for submission under 37 CFR 1.99) Examiner Name G. Elkins Attorney Docket Number 104035.271436

U.S.PATENTS

				U.S.PAIENIS				WEITHOVE		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Date	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines when ant Passages or Releves as Appear	
	1	4344533		1982-0	8-17	Olsen				
	2	5085323		1992-0	2-04	Kuchenbecke	retal.			
	3	6209292	B1	2001-0	4-03	Krahn				
If you wisi	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date				Relev	s,Columns,Lines when ant Passages or Releves as Appear	
	1									
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	blease click the Ad	d buttor	n. Add	
				FOREK	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>			Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	39 32 441	DE		A1	1991-04-11	Beiersdorf AG			V

#### 

		NON-PATEN	T LITERATURE DOCUMENTS Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue numl publisher, city and/or country where publisher.		osium, catalog, etc), date, pages(s), volume-issue number(s),	T5	
	1	German Search Report dated June 3, 200	for corresponding Application No. DE 102 52 683.	
If you wish	n to a	l dd additional non-patent literature docun	nent citation information please click the Add button Add	_
		EX	AMINER SIGNATURE	
Evaminer	Sians	ature.	Date Considered	

See Kind Codes of USPTD Patent Documents at winer <u>USPTD\_GDV</u> or MPEP 991.64. If Enter office that issued the document, by the two-letter code (WIPD Standard ST.3.) If Post Japanese patent documents, his volcation of the year of the regist of the register of the present must preced the serial number of the plaint document. The preceding the patent documents with the preceding the patent documents of the patent document under WIPD Standard ST.1.68 (passed. - Application to place a cross control of the patent document under WIPD Standard ST.1.68 (passed. - Application to place a cross control of the patent documents and the patent documents of the patent documents are patent documents.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10712131		
Filing Date		2003-11-13		
First Named Inventor	Scha	bert		
Art Unit		3727		
Examiner Name	G. El	kins		
Attorney Docket Number		104035.271436		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the approp	riate selection(s):
--	---------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

## ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/rcagle/	Date (YYYY-MM-DD)	2006-08-15
Name/Print	Ryan W. Cagle	Registration Number	47,468

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet for disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via fifed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.